Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube Sells 10,736 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 10,736 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $208,922.56. Following the sale, the chief executive officer now directly owns 351,239 shares of the company’s stock, valued at $6,835,110.94. This represents a 2.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Travere Therapeutics Stock Up 6.9 %

Shares of Travere Therapeutics stock opened at $20.81 on Friday. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -4.57 and a beta of 0.70. The stock has a 50-day simple moving average of $18.28 and a 200-day simple moving average of $14.79. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $20.89. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. During the same period in the previous year, the company earned ($1.17) earnings per share. The company’s revenue was up 69.6% compared to the same quarter last year. On average, equities research analysts expect that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

A number of large investors have recently bought and sold shares of TVTX. R Squared Ltd acquired a new stake in shares of Travere Therapeutics in the fourth quarter worth about $53,000. CWM LLC raised its stake in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after acquiring an additional 3,065 shares in the last quarter. Quarry LP acquired a new stake in Travere Therapeutics in the 3rd quarter worth approximately $105,000. Baader Bank Aktiengesellschaft bought a new stake in Travere Therapeutics during the fourth quarter worth approximately $192,000. Finally, Diversified Trust Co acquired a new position in Travere Therapeutics during the third quarter valued at approximately $161,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TVTX shares. Citigroup cut their price target on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, September 27th. Canaccord Genuity Group cut their target price on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. HC Wainwright raised their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Leerink Partners reissued an “outperform” rating and set a $20.00 price target on shares of Travere Therapeutics in a research report on Tuesday, October 8th. Finally, Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.